Navigation Links
DiFUSION Technologies Completes Successful Antimicrobial Implant Animal Trial

AUSTIN, Texas, Oct. 7 /PRNewswire/ -- DiFUSION Technologies is a medical device company focused on the development and commercialization of its proprietary CleanFUZE™ antimicrobial technology for orthopedic implants and its new Xiphos™ line of Posterior Interbody products for spinal surgery.

"Post-operative infections are a major problem today, and with the further proliferation of drug resistant bacteria, preventing the infections is even more important than it has been in the past.  Having materials that actively fight against post-operative infections is an important step towards eliminating this devastating problem," said Dr. Nitin N. Bhatia, MD, Chief, Spine Service Co-Director, Combined Spine Program, Residency Program Director Dept. of Orthopedic Surgery, University of California, Irvine.

DiFUSION's recently completed third party animal tests showed that after introducing Methicillin Resistant Staphylococcus Aureus (MRSA), a common, aggressive, multi-drug resistant bacterium, to rabbits implanted with DiFUSION's proprietary CleanFUZE orthobiologic polymer, the animals showed little visible inflammation or infection. Microscopic analysis of the same samples showed CleanFUZE to be up to 99.99% effective in eradicating the active infection.

"This is the first time any potential biomaterial has shown, in an animal model, to significantly reduce the numbers of an infectious agent as well as the local tissue markers of actual infection," said Matthew Geck, MD, cofounder of DiFUSION. "This was done using a safe and tissue friendly, pharmacologic dosing of silver with our innovative and proprietary biomaterial that combines the structural properties of PEEK with the controlled elution of cationic silver. This biomaterial has the potential to be the base material for a whole range of spine and orthopedic implants."

According to a variety of large published studies, post-operative surgical site infections (SSIs) occur in up to 20% of patients costing the U.S. health care system billions of dollars annually. In fact, a single SSI can cost up to $100,000 per incident and result in significant injury, disability or even death. Complicating the problem of SSIs is growth in the number of antibiotic resistant bacterial strains such as MRSA, which are associated with rising infection rates in hospitals. With few available treatment options hospitals, surgeons and payers have shifted their focus toward new methods of prevention as an essential tool to avoid SSIs.

"The results from the in vivo animal testing are very encouraging," remarked Gary Ghiselli, MD, chairman of the DiFUSION scientific advisory board. "They represent a big step towards establishing the ability of CleanFUZE to reduce, and possibly eliminate, the incidence of post-operative surgical infections. This has obvious wide-reaching potential in spinal surgery and in orthopedics in general, to reduce complications and improve patient outcomes."

DiFUSION's polymer is a blend of a cationic matrix which carries pure silver, an effective broad spectrum antimicrobial, and a PEEK polymer which are combined through a proprietary process to create CleanFUZE. The resulting material can be used to create a variety of orthopedic devices that release silver ions into the surrounding tissue allowing for controlled, continual dosing over a four to six week timeframe, resulting in significantly increased efficacy.

"CleanFUZE orthobiologic PEEK is a self-sterilizing polymer which this study has shown to be up to 99.99% effective in eliminating post operative infection," said John Kaelblein, President of DiFUSION.  "CleanFUZE could have a real impact on patients and the healthcare system in general. These results represent a huge step toward bringing CleanFUZE to market."

About DiFUSION Technologies

Founded in 2008 in Austin, Texas, DiFUSION Technologies, Inc. is a medical device company focused on reducing the rising incidence of surgical site infections in orthopedic and spine surgery through the development of a suite of patented antimicrobial orthobiologic polymeric implants. Initially focusing on the multi-billion dollar spinal implant market, the company has developed a technology with applicability across a variety of orthopedic segments using well characterized implants with benefits for the patient, surgeon, hospital and payer. For more information about DiFUSION Technologies, visit

SOURCE DiFUSION Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DiFUSION Technologies Adds Accomplished Senior Management Team
2. DiFUSION Technologies Receives 510(k) Clearance of Xiphos™ Interbody Implants for Spinal Fusion
3. IDEV Technologies Completes $46 Million Preferred Stock Financing With Piper Jaffray and Additional Strategic Investor
4. medSage Technologies Introduces Revolutionary Universal CPAP Monitor
5. All-Time High in Q Orders for Wound Management Technologies, Inc.
6. Reportlinker Adds Nanobiotechnologies - Applications, Markets and Companies
7. Thompson Group Acquires Hamilton Sundstrands Applied Instrument Technologies
8. Objet Geometries and Javelin Technologies Form Strategic Distribution Partnership for 3D Printers
9. Delta Health Technologies ClinicalVirtuoso™ Targets Homecare Therapists
10. Medisafe 1 Technologies Successfully Tests Prototype of Patented Syringe Locking Device
11. Palatin Technologies to Present at 9th Annual BIO Investor Forum
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  The ... norm in U.S. medical imaging is on ... popular accountable care payer-provider contracts are set ... in their wake, alter provider-vendor relationships. The ... will push forward new purchasing frameworks in ...
(Date:11/30/2015)... , Nov. 30, 2015 Oramed Pharmaceuticals Inc. ... on the development of oral drug delivery systems, announced ... valued at up to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., ... insulin capsule, ORMD-0801, in China , ... Macau . The agreements were signed at the ...
(Date:11/30/2015)... Nov. 30, 2015 iCAD, Inc. (Nasdaq: ... feature its latest solutions for advanced image analysis ... cancer at the Radiological Society of North American ... from November 29 to December 4, ... including iReveal®, an automated breast density assessment solution, ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... PYA’s latest white paper, “ PYA ... main “pain point” for merging or aligning healthcare provider organizations—when mergers and other ... This quick-read guidance suggests that failing to recognize the power of an ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of ... SACC-USA . Gary has spent a significant amount of time in Sweden since ...
(Date:12/1/2015)... ... , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won ... order will be from the China Disabled Persons’ Federation, a central government association, for ... for children and adults suffering from severe and profound hearing loss . The ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. This ... patient care experience, and propose exciting enhancements to the medical landscape. , The ...
(Date:11/30/2015)... ... 2015 , ... Third Molar SEO , one of ... launched a sleek, mobile-ready and user-centric redesigned website. , Vivek Srivastava, founder and ... the benefits that its SEO services provide to dentists and why Third Molar ...
Breaking Medicine News(10 mins):